As an emerging drug development company Eribis will have the need for venture capital.  Today the Company is financed through Karolinska Development, who are represented in the Board. We believe that the project should be driven cost effectively and that investors should feel confidence in our willingness and ability to deliver great value for their investment funds through high quality science, research & development in a setting that is optimal for business development – building value in the IPR.